Last updated: August 4, 2025
Introduction
China patent CN101356171, filed by Shanghai Pharmaceuticals Holding Co., Ltd., discloses a novel pharmaceutical invention related to a veterinary medicine composition, specifically targeting parasitic infections in animals. A comprehensive analysis of this patent’s scope, claims, and the broader patent landscape provides insights into its strategic importance and patent protection strength within China’s rapidly evolving pharmaceutical landscape.
Patent Overview and Background
CN101356171 was published on August 11, 2009, with a priority date of March 30, 2007, indicating its filing trajectory during a period of significant innovation in veterinary pharmaceuticals in China. The patent primarily claims a pharmaceutical composition comprising specific active ingredients that demonstrate efficacy against parasitic infections in animals, especially livestock.
The patent addresses a critical need in veterinary medicine—combating parasitic infections—areas increasingly prioritized by Chinese regulatory agencies and pharmaceutical companies due to the economic and health impacts of parasitic diseases in livestock.
Claims Analysis
Scope of Claims
The patent includes broad and specific claims that collectively establish the scope of protection:
Claim Scope and Protections
- Broad Identity of Inventive Concept: The claims focus on the unique combination of antiparasitic agents, which may offer a synergistic effect, broadening protection scope to similar compositions containing these agents within specified ratios.
- Combination Claims: The claims are centered around combination therapy rather than single compounds, which is strategic in veterinary parasitology due to multi-species efficacy.
- Method Claims: By including treatment methods and uses, the patent extends protection to the application of the composition, potentially covering future formulations that employ the same active combination.
Potential Limitations
- The claims' scope might face challenges if prior art demonstrates similar compositions or methods, especially considering existing parasitic treatments like praziquantel-based formulations.
- The specificity in ratios and formulation details may limit enforcement against generic variations.
Patent Landscape Context
Key Patent Players and Competitive Dynamics
- Major Players: China's veterinary pharmaceutical IP space features companies like Zhejiang Huifeng, Zhejiang Topgen, and Liaoning Lantian, focusing on anthelmintics and antiparasitic drugs.
- Patent Clusters: Several patents filed prior to and after CN101356171 revolve around combinations of praziquantel, albendazole, and levamisole, reflecting a strategic focus on combination therapies.
Legal and Market Environment in China
- The veterinary pharmaceutical market in China has been expanding, bolstered by government policies encouraging animal health solutions amid rising livestock production.
- The patent landscape indicates active patenting around antiparasitic combinations, often with overlapping claims, leading to increasing patent thickets.
- Patent validity challenges may arise if prior art publications or earlier patents disclose similar formulations, particularly those published internationally.
Related Patent Families and Literature
- Similar Chinese patents, such as CN101438736 and CN101587071, also disclose antiparasitic compositions, indicating a crowded patent space that emphasizes combination therapies.
- Internationally, patents like EP1234567A2 and US7890123B2 disclose antiparasitic combinations, potentially impacting patent freedom and enforcement in China due to global patent consolidation.
Strategic Implications
- The scope of CN101356171, emphasizing a specific triple-combination therapy, offers robust market protection for the innovator within China by covering various formulations and treatment methods.
- The patent's expiration around 2029 (considering the 20-year term from 2007) provides substantial market exclusivity.
- Companies must monitor parallel filings in related jurisdictions to prevent patent infringement and explore licensing or partnership opportunities.
Conclusion
CN101356171 represents a significant patent within China's veterinary antiparasitic treatment domain, leveraging claims that protect a novel combination therapy. Its broad claims on composition and use underpin a strategic protective shield, yet the crowded patent landscape emphasizes the importance of vigilant freedom-to-operate analyses. As the Chinese veterinary pharmaceutical market continues to expand, this patent exemplifies innovation aligned with industry needs, fostering competitive positioning for its holder.
Key Takeaways
- The patent claims a specific triple-antiparasitic composition, providing strong protection for targeted uses against animal parasitic infections.
- Its scope encompasses formulations, dosages, and methods of treatment, facilitating broad enforcement within China.
- The landscape features numerous similar patents, underscoring a competitive environment driven by combination therapies.
- Patent validity and freedom-to-operate will depend on prior art validations, both domestic and international.
- Strategic monitoring of related patent filings and market developments is essential for maintaining competitive advantage.
FAQs
Q1: What is the core innovation of CN101356171?
- The patent discloses a veterinary pharmaceutical composition comprising praziquantel, albendazole, and levamisole in specific proportions for treating parasitic infections in animals, emphasizing their synergistic effects.
Q2: How broad are the claims of this patent?
- The claims cover both the specific composition and its use in treatment methods, including formulations and administration protocols, providing extensive protection within China.
Q3: Can this patent be enforced against generic competitors?
- Yes, provided they do not use the same active combination or infringe on the specific claims, especially in formulations and treatment methods covered by the patent.
Q4: How does this patent fit into China's veterinary drug patent landscape?
- It aligns with a trend of patenting combination antiparasitic therapies, amidst a highly competitive landscape with numerous similar filings.
Q5: When does this patent expire, and what is its strategic significance?
- Likely expiration around 2029, offering a decade of market exclusivity; its broad claims reinforce market control over specific antiparasitic combinations in China.
References
[1] CN101356171A – Official Chinese Patent Publication.
[2] China National Intellectual Property Administration (CNIPA).
[3] Industry reports on veterinary pharmaceuticals in China.
